Empagliflozin
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
<scene name='10/1025379/Cv/2'>Human SGLT2-MAP17 complex bound with empagliflozin</scene> ([[7vsi]]). | <scene name='10/1025379/Cv/2'>Human SGLT2-MAP17 complex bound with empagliflozin</scene> ([[7vsi]]). | ||
| + | |||
| + | <scene name='10/1025379/Cv/4'>Empagliflozin binding site</scene>. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:01, 28 January 2024
| |||||||||||
References
- ↑ Abdul-Ghani MA, DeFronzo RA. Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus. Endocr Pract. 2008 Sep;14(6):782-90. PMID:18996802 doi:10.4158/EP.14.6.782
- ↑ Nair S, Wilding JP. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab. 2010 Jan;95(1):34-42. PMID:19892839 doi:10.1210/jc.2009-0473
- ↑ Bays H. From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus. Curr Med Res Opin. 2009 Mar;25(3):671-81. PMID:19232040 doi:10.1185/03007990802710422
